(NASDAQ: NUVL) Nuvalent's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 85.29%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.87%.
Nuvalent's revenue in 2025 is $0.On average, 8 Wall Street analysts forecast NUVL's revenue for 2026 to be $1,534,967,770, with the lowest NUVL revenue forecast at $306,445,557, and the highest NUVL revenue forecast at $4,369,553,122. On average, 6 Wall Street analysts forecast NUVL's revenue for 2027 to be $11,360,477,594, with the lowest NUVL revenue forecast at $2,848,141,062, and the highest NUVL revenue forecast at $18,225,218,600.
In 2028, NUVL is forecast to generate $28,849,650,018 in revenue, with the lowest revenue forecast at $11,111,355,382 and the highest revenue forecast at $35,492,884,965.